Medtronic says new data reinforce IN.PACT Admiral as 'durable, frontline option'
Medtronic said data presented in two late-breaking clinical trial presentations at the Vascular Interventional Advances 2018 conference reinforce the durability, safety, and effectiveness of the IN.PACT Admiral drug-coated balloon in patients with peripheral artery disease in the superficial femoral and popliteal arteries. "Since the entrance of DCBs into the market several years ago, we have seen a shift towards the use of this technology as a frontline therapy to treat patients with PAD. This is especially true of IN.PACT Admiral DCB, which has consistently proven to be one of the safest, most effective, and durable therapies in treating patients across the spectrum of femoral-popliteal disease. We are proud to have become the first company to share five-year data on a commercially-available DCB and the first to present outcomes from the largest pooled analysis in the peripheral space to-date. We believe this new evidence will give physicians the confidence that IN.PACT Admiral DCB is the preferred first line therapy for patients who suffer with femoral-popliteal disease," said Mark Pacyna, vice president and general manager of the Peripheral business in the Medtronic Cardiac & Vascular Group. "